M. D. ANDERSON CANCER CENTER ACQUIRES LEKSELL GAMMA KNIFE PERFEXION FOR TARGETED BRAIN LESION TREATMENTS

M. D. ANDERSON CANCER CENTER ACQUIRES LEKSELL GAMMA KNIFE PERFEXION FOR TARGETED
BRAIN LESION TREATMENTS

Press Release 
Stockholm, Sweden, February 25, 2008

The University of Texas M. D. Anderson Cancer Center (Houston, Texas) will add
Elekta's Leksell Gamma Knife® Perfexion™, an advanced radiosurgery device
specifically designed to treat one or more lesions in the head in a single
session, to their radiation oncology department.


“Leksell Gamma Knife Perfexion suits our clinical needs,” says Eric Chang, M.D.,
Director of M. D. Anderson's Central Nervous System Stereotactic Radiation
Program. “The device will be used initially to treat primary brain and skull
base tumors as well as single and multiple brain metastases in a single
session.” 

Designed to extend the system's reach down to the level of the skull base and
cervical spine, Perfexion is scheduled to be delivered to M. D. Anderson by
March 2009 and should be operational by mid-2009, he adds.  

“Elekta is committed to supporting radiosurgery and neuro-oncology by providing
highly refined tools that support specific clinical objectives, yet share a
common foundation in terms of image and information management,” says Joseph K.
Jachinowski, President and CEO of Elekta North America. “The result is a
complete line of stereotactic treatment solutions designed to meet the goals of
any type of radiosurgery program.”


For further information, please contact:

Michelle Lee, Director, Marketing Services, Elekta Inc. 
Tel: +1 770-670-2447, michelle.lee@elekta.com

Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   


About Leksell Gamma Knife® Perfexion™

Leksell Gamma Knife® Perfexion™ is the most advanced radiosurgery system on the
market for head treatments and the latest version of Elekta's Leksell Gamma
Knife, a complete system for intracranial stereotactic radiosurgery or Gamma
Knife® surgery. Perfexion, now in clinical use in 23 locations across North
America, has been specifically designed to improve patient comfort and treatment
time through advanced automation. Treatment applications have also been extended
to include all areas of the head, down to the regions of the cervical spine. 

The non-invasive treatment is shaped by 192 simultaneously focused beams of
ionizing radiation that have sufficient penetration to reach even the most
deeply seated tumors. The system delivers prescribed doses/shots of radiation,
in compliance with a treatment plan, to the exact target site, thereby sparing
surrounding tissues. Gamma Knife surgery has many advantages. The risk of
complications, as compared to open surgery, is less and it is a gentler form of
treatment for the patient. Gamma Knife surgery can normally be performed in a
day, and convalescence is extremely short. The technique, supported by over
three decades of clinical practice, is performed for over 50,000 patients each
year. To date, more than 500,000 patients around the world have undergone Gamma
Knife surgery. 

About M. D. Anderson Cancer Center

The University of Texas M. D. Anderson Cancer Center is located on the campus of
the Texas Medical Center in Houston, Texas. It is one of the world's most
respected centers devoted exclusively to cancer patient care, research,
education and prevention. M. D. Anderson Cancer Center is one of the nation's
original three Comprehensive Cancer Centers designated by the National Cancer
Act of 1971 and is one of 41 National Cancer Institute-designated Comprehensive
Cancer Centers today.

In 2008, U.S. News and World Report's “America's Best Hospitals” survey ranked
M. D. Anderson as the top hospital in the nation for cancer care. M. D. Anderson
has achieved the top ranking four times in the past six years and has ranked as
one of the top two hospitals for cancer care for 19 years, since the magazine
began its annual survey in 1990.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.